Prothena Announces Corporate Restructuring
'We have incredible Prothenians who are among the industry's most talented professionals and have dedicated their careers to advancing new treatments for patients,' said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. 'I want to express my sincere gratitude to each Prothenian being affected by today's announcement and thank them for their passion toward our mission to treat diseases caused by protein dysregulation.'
The board, management, and Company's financial advisors are collectively evaluating a comprehensive range of business options to best serve the interest of its shareholders that consider the implications of multiple recent and upcoming milestones, including:
Earlier this week Roche announced that it will advance prasinezumab into Phase 3 development for early-stage Parkinson's disease
Company expects initial data in August from Phase 1 ASCENT clinical trials of its wholly owned PRX012 program in Alzheimer's disease
Novo Nordisk expects to share data from its Phase 2 clinical trial evaluating coramitug for ATTR-CM in the second half of 2025
Company expects to complete a Phase 1 clinical trial for PRX019 in collaboration with Bristol Myers Squibb in 2026
Bristol Myers Squibb expects to complete a Phase 2 TargetTau-1 clinical trial evaluating BMS-986446 in Alzheimer's disease in 2027
Company has potential to receive up to $105 million in 2026 for clinical milestones from various partnered programs.
Revised 2025 Financial Guidance
Based on this reorganization, the Company is revising its full year 2025 financial guidance and expects its 2025 net cash burn from operating and investing activities to be $170 to $178 million and to end the year with approximately $298 million (midpoint) in cash, cash equivalents, and restricted cash. The estimated 2025 net cash burn from operating and investing activities is primarily driven by an estimated net loss of $240 to $248 million, which includes an estimated $36 million of non-cash share-based compensation expense and a $45 million non-cash income tax expense to book a full valuation allowance against its U.S. deferred tax assets. The estimated 2025 net loss includes $105 to $110 million of operating expenses associated with birtamimab and the Company's reorganization, including research, development, manufacturing and pre-commercial expenses, severance costs and contract termination fees related to manufacturing obligations, and approximately $12 million of non-cash share-based compensation expense. Therefore, the Company expects the discontinuation of birtamimab development will result in an approximate decrease of $96 million (midpoint) in annualized net cash burn.
Please see the form 8-K the Company filed today for additional financial and other details.
About Prothena
Prothena Corporation plc is a clinical-stage biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases. For more information, please visit the Company's website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund completion of our ongoing clinical trials; expected milestones in 2025, 2026, and beyond, including upcoming initial data from the Phase 1 ASCENT clinical trials on PRX012 in Alzheimer's disease expected in August 2025, and program updates from our partners at Novo Nordisk expected in the second half of 2025, and Bristol Myers Squibb expected in 2026; the estimates of expenses associated with the reduction in workforce prove inaccurate; we incur greater than estimated expenses in connection with the reduction in workforce; our business, financial condition or operating results are adversely affected by the reduction in workforce; our anticipated net cash burn from operating and investing activities for 2025 and expected cash balance at the end of 2025; and our estimated net loss and non-cash share-based compensation expense for 2025; and our continuing evaluation of business options. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to uncertainties related to the completion of operational and financial closing procedures, audit adjustments and other developments that may arise that would require adjustments to the preliminary financial results included in this press release, as well as those described in the 'Risk Factors' sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 8, 2025, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
CHTR BREAKING NEWS: Charter Communications, Inc. 18% Stock Drop Results in Class Action -- Investors are Notified to Contact BFA Law by October 14 Class Action Deadline
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Charter Communications, Inc. (NASDAQ: CHTR) and certain of the Company's senior executives for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Charter Communications, Inc. (NASDAQ: CHTR) for potential violations of the federal securities laws. Share If you invested in Charter, you are encouraged to obtain additional information by visiting: Investors have until October 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Charter securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Sandoval v. Charter Communications, Inc., No. 1:25-cv-06747. Why Was Charter Sued Under the Federal Securities Laws? Charter is a leading broadband, or high-speed internet, connectivity company and cable operator. Charter participated in the FCC's Affordable Connectivity Program ('ACP'), which provided funding to Charter in exchange for subsidizing high-speed internet plans for low-income households. In June 2024, lack of federal funding caused the ACP to end, which led to customer declines at Charter. During the relevant period, Charter told investors that the Company was executing a plan to minimize and move beyond risks that the end of the ACP had on customer declines and earnings. The Company stated that it had 'managed the end of the affordable connectivity program successfully' and that '[t]he impact of the elimination of the ACP is now behind us.' As alleged, in truth, the impact from the ACP's elimination was not behind Charter as the Company continued to experience internet customer and revenue declines from the program's end. The Stock Declines as the Truth Is Revealed On July 25, 2025, Charter announced its second quarter 2025 financial results. The Company reported that total internet customers decreased by 117,000 during the quarter, which included approximately 50,000 disconnects related to the end of the ACP, nearly double from the prior quarter. On this news, the price of Charter stock declined $70.25 per share, or 18.4%, from a closing price of $380.00 per share on July 24, 2025, to $309.75 per share on July 25, 2025. Click here for more information: . What Can You Do? If you invested in Charter you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Business Wire
a minute ago
- Business Wire
Hirsch's Velocity Access Control Wins 2025 Secure Campus Award for Advancing Safety in K-12 and Higher Education
SANTA ANA, Calif.--(BUSINESS WIRE)--Hirsch, a global leader in high-security access control, video, perimeter protection, and identity authentication, is proud to announce that its Velocity security management system has earned the 2025 Secure Campus Award from Security Today and Campus Security Today in the Access Control Software category. Hirsch Velocity helps educational leaders not only secure their campuses but also create a culture of trust, readiness, and operational efficiency. Our customers in education measure success in lives protected, disruptions avoided, and trust maintained. Share This recognition reflects Velocity's proven track record of transforming campus safety—protecting students, faculty, staff, and visitors across K-12 districts, community colleges, and large universities. By delivering a unified, intuitive, and scalable platform, Velocity addresses the diverse safety needs of educational environments, from single-building schools to multi-campus institutions. Purpose-Built for Education Velocity was designed with the realities of education in mind — balancing safety, compliance, and ease of use. It integrates: Access Control and Role-Based Permissions – Preventing unauthorized access and credential misuse Real-Time Alarm Monitoring – Accelerating incident response through automated workflows and centralized control Lockdown and Emergency Protocols – Enabling fast, coordinated action to prevent escalation of events and protect people and property Video Integration – Pairing Velocity with Velocity Vision VMS for complete event correlation and first-responder situational awareness and coordination in a single interface Health and Safety Tools – Including contact tracing and entry tracking to support wellness protocols Proven Results in the Field Our edge-to-core collaborations with educational institutions yield measurable improvements: At a major university, Velocity cut incident response times by enabling security teams to identify and address threats in real time from one dashboard. In a K-12 school district, role-based access control reduced unauthorized entries, protecting students and staff while maintaining a welcoming campus environment. For multiple community colleges, streamlined credential management reduced administrative workload for IT teams by up to 25%, freeing resources for other technology initiatives. In a unified school district, Hirsch FIDO2 Security Keys delivered multi-factor authentication for 2500 employees across multiple school sites to enhance cybersecurity and meet stringent insurance mandates, without relying on personal devices for authentication. Scalable, Compliant, and Future-Ready Velocity scales easily to meet the needs of institutions of all sizes and budgets. Whether protecting a single elementary school or a network of university campuses, it supports: Compliance with federal standards for grant-funded projects Flexible growth as security needs evolve Centralized management for dispersed facilities Leadership Perspective 'This award recognizes our deep partnership with schools, colleges, and universities who share our vision of safer learning environments,' said Scott Elliott, Chief Revenue and Marketing Officer, Hirsch. 'Velocity helps educational leaders not only secure their campuses but also create a culture of trust, readiness, and operational efficiency. Our customers in education measure success in lives protected, disruptions avoided, and trust maintained. Velocity delivers on that promise, combining advanced security technology with a focus on real-world results.' Partner with Hirsch for a Safer Campus To learn how Velocity can help your district or campus strengthen safety, contact sales@ or +1 888.809.8890. About Hirsch Hirsch is a global leader in high-security access control, video intelligence, perimeter protection, and identity authentication. With a focus on unified, brilliantly simple platforms, Hirsch empowers organizations — including hundreds of schools, universities, and colleges worldwide — to protect people, safeguard critical assets, streamline operations, and meet compliance standards. Learn more at
Business Wire
a minute ago
- Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer's activities in the 18 countries of the European Union that are presently participating in the UPC. The European Patent Office's recent grant of the '265 Patent to Enanta was published in the European Patent Bulletin today. The '265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The '265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer Inc. Under UPC procedures, a hearing on the infringement action is expected to occur within the UPC's published 12-month target, with the decision rendered within weeks thereafter. If the UPC determines there has been infringement, subsequent proceedings would be required to determine damages. All timelines remain subject to potential rights of appeal and other customary proceedings in European patent litigation. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ® (U.S.) and MAVIRET ® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. Forward Looking Statements Disclaimer This press release contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in 'Risk Factors' in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.
